Group 1 - The company completed the acquisition of 100% equity in Guangdong Xiantong Pharmaceutical Co., Ltd. for RMB 220 million on August 22, 2022 [1] - The acquisition involved Beijing Xiantongyuan Pharmaceutical Technology Co., Ltd. holding 90% and Li Yinqiang holding 10% of the equity [1] - The company has published relevant announcements regarding the acquisition on multiple financial news platforms [1] Group 2 - The performance commitment period for the acquisition is from April 2022 to December 2025, with specific net profit targets set for Guangdong Xiantong [2] - If the cumulative net profit achieved by Guangdong Xiantong is less than 90% of the committed net profit, the original shareholders are required to compensate the company up to a maximum of RMB 60 million [2] - The actual net profit for 2024 was reported at RMB 508.45 million, failing to meet the performance commitment, leading to a compensation obligation of RMB 57.48 million [2][3] Group 3 - As of April 21, 2025, the company received a total of RMB 4,777.46 million in performance compensation from the original shareholders [3] - The compensation included RMB 4,299.71 million from Beijing Xiantongyuan and RMB 477.75 million from Li Yinqiang [3] - The performance commitment obligations for the 2024 fiscal year have been fulfilled as per the agreement [3]